table network network 2
demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only observational study
COVID 19 all comersCOVID-19 mild to moderateCOVID-19 severe or critically
COVID 19 hospitalizedCOVID 19 all comersCOVID-19 mild to moderateCOVID-19 severe or critically
Immunostimulants drugs
convalescent plasma treatment ConPlas-19 CPC-SARS COPLA-II trial Bennett-Guerrero COP-COVID-19 NCT04403477 ... CONTAIN COVID-19 NCT04442191 LACCPT ASCOT PERUCONPLASMA Co-CLARITY Baldeon Abolghasemi PC/COVID-19 DAWN-Plasma RECOVERY ... NCT04528368 Menichetti NCT04397757 NCT04385199 Salman Holm K ConCOVID ... Salazar PLACO-COVID Kirenga CCAP-2 CONCOR-1 CONFIDENT LIFESAVER Libster PLACID CP-COVID-19 RECOVER ILBS-COVID-02 ... PICP19 ... Pouladzadeh Rasheed AlQahtani Duan Hegerova O’Donnell PlasmAr Sekine ... Li Sean Joyner CAPSID REMAP-CAP ... Bihariesingh-Sanchit ... Ray
Early convalescent plasma. Balcells
immunoglobulin therapy Sakoulas Parikh Raman Tabarsi Gharebaghi
interferon Wang ... Wang Cai -FAVIPIRAVIR Cai -FAVIPIRAVIR
IFN beta-1a SOLIDARITY ... Kalil ... Davoudi-Monfared Darazam ...
high-dose IFN beta-1a Darazam
IFN beta-1b Darazam ... Rahmani
IFN gamma Esquivel-Moynelo
inhaled interferon
IFN alpha
pegylated interferon-α2b Pandit Shashi Bhushan
recombinant super-compound interferon rSIFN-co Li
SNG001 inhaled interferon beta SPRINTER Synairgen SG016
interferon / TFF2 Fu
peginterferon Jagannathan
PNB001 Lattmann
neutralizing antibody ITAC
amubarvimab/romlusevimab (BRII-196 and BRII-198-Brii Biosciences) ACTIV-3 ...
bamlanivimab monotherapy ACTIV-3/TICO LY-CoV555
casirivimab/imdevimab (Ronapreve) RECOVERY ... Suzuki Somersan-Karakaya ...
cilgavimab and tixagevimab (Evusheld) ACTIV-3/TICO ... Chen
equine polyclonal antibodies INM005 Lopardo
sotrovimab (Xevudy; VIR-7831) ACTIV-3/ TICO ...

2 studies excluded by filtering options 2

5569 Dai W, 2020 2134excludednot a RCThigh risk of bias
10178 Bargay-Lleonart, 2022 210excludedrisk of bias not avaialble

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons